Donor cells join forces with antibody to fight tough lymphomas
Disease control
Recruiting now
This early-phase trial tests a combination of donated natural killer (NK) immune cells and a drug called mogamulizumab for people with certain T-cell lymphomas that have returned or not responded to prior treatment. The study aims to find the safest dose and see if the combinatio…
Phase: PHASE1 • Sponsor: John Reneau • Aim: Disease control
Last updated May 14, 2026 12:06 UTC